Sign in

    Dan Akshit

    Senior Equity Analyst at Pareto Securities

    Dan Akschuti is a Senior Equity Analyst at Pareto Securities specializing in Nordic small- and mid-cap equities, with a particular focus on the biotechnology and life sciences sectors. He covers companies such as BioInvent, Oculis, and Camurus, and has driven strong portfolio performance with his 2024 top picks delivering an 18.5% return, outpacing the OMXSGI index. Akschuti has been part of Pareto Securities since at least early 2024, preceding which his detailed previous experience is not broadly documented. He is recognized regionally for his expertise, contributing investment insights at major conferences, and operates under the compliance standards expected of senior research analysts in European financial markets.

    Dan Akshit's questions to Amylyx Pharmaceuticals (AMLX) leadership

    Dan Akshit's questions to Amylyx Pharmaceuticals (AMLX) leadership • Q1 2025

    Question

    Dan Akshit of Pareto Securities asked how Avexitide compares competitively to other potential entrants in the post-bariatric hypoglycemia (PBH) space, such as somatostatin analogs. He also inquired about the expected placebo response in the Phase III LUCIDITY trial.

    Answer

    Co-CEO Justin Klee emphasized Avexitide's strong position, noting it is in Phase III with FDA Breakthrough Therapy Designation based on five prior successful trials. Co-CEO Joshua Cohen reiterated that the designation implies a potential benefit over existing options, of which there are none approved. Regarding the placebo rate, Justin Klee stated that no meaningful placebo effect was seen in the Phase II study, but the Phase III trial is robustly powered to account for a potential placebo response regardless.

    Ask Fintool Equity Research AI